Literature DB >> 7836770

Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung.

D L Haviland1, R L McCoy, W T Whitehead, H Akama, E P Molmenti, A Brown, J C Haviland, W C Parks, D H Perlmutter, R A Wetsel.   

Abstract

The small-complement C5 activation fragment, C5a, is a potent phlogistic molecule that, on binding to the C5a Receptor (C5aR), mediates contraction of smooth muscle, enhances vascular permeability, and promotes leukocyte functions such as directed chemotaxis, degranulation, mediator release, and production of superoxide anions. Although C5aR expression has traditionally been thought to be limited primarily to myeloid blood cells, including neutrophils, monocytes, macrophages, and eosinophils, we report here that C5aR is expressed by liver and lung cells as well as by cells in several other tissues. By Northern blot analysis, it was determined that mouse liver, baboon liver, human liver, and the human hepatoma-derived cell line HepG2 express a normal size (2.3 kb) C5aR mRNA; in HepG2 cells, the quantity of C5aR mRNA was comparable to that contained in dbcAMP-differentiated U937 cells. HepG2 cells were demonstrated to express the C5aR on their cell surface by flow cytometric and immunofluorescence analyses as well as by 125I-C5a binding assays. The binding data indicated that HepG2 cells express a single class of C5aR with a Kd of 1.18 nM and approximately 28,000 receptors per cell. In vivo expression of C5aR in human liver cells was demonstrated by in situ hybridization and immunohistochemistry analyses. Northern blot analysis of murine and baboon organs shows that, in addition to the liver, other tissues express C5aR mRNA in significant quantities, including the spleen, lung, heart, kidney, and intestine. Moreover, mice treated with LPS show a large increase in C5aR mRNA in all these tissues except the intestine. Immunostaining of human lung tissue demonstrated that bronchial and alveolar epithelial cells, as well as vascular smooth muscle and endothelial cells, also express the C5aR. Collectively, these data indicate that the C5aR is expressed in several different types of cells in liver and lung, and in yet undetermined cell types in spleen, heart, intestine, and kidney. Furthermore, these data suggest that the C5a anaphylatoxin mediates previously unrecognized functions by binding to tissue cells that express the C5aR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7836770

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  The C5a receptor is expressed by human renal proximal tubular epithelial cells.

Authors:  R Zahedi; M Braun; R A Wetsel; B H Ault; A Khan; T R Welch; M Frenzke; A E Davis
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells.

Authors:  A Fayyazi; O Scheel; T Werfel; S Schweyer; M Oppermann; O Götze; H J Radzun; J Zwirner
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 3.  New insights into cellular mechanisms during sepsis.

Authors:  Laszlo M Hoesel; Hongwei Gao; Peter A Ward
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  The role of complement in danger sensing and transmission.

Authors:  Jörg Köhl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins.

Authors:  Monali M Bera; Bao Lu; Thomas R Martin; Shun Cui; Lawrence M Rhein; Craig Gerard; Norma P Gerard
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

6.  Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.

Authors:  Hongmei Gu; Amanda J Fisher; Elizabeth A Mickler; Frank Duerson; Oscar W Cummings; Marc Peters-Golden; Homer L Twigg; Trent M Woodruff; David S Wilkes; Ragini Vittal
Journal:  FASEB J       Date:  2016-03-08       Impact factor: 5.191

Review 7.  [Traumatic brain injury: impact on timing and modality of fracture care].

Authors:  P F Stahel; W Ertel; C E Heyde
Journal:  Orthopade       Date:  2005-09       Impact factor: 1.087

8.  Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.

Authors:  M Fung; M Lu; H Fure; W Sun; C Sun; N Y Shi; Y Dou; J Su; X Swanson; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

Review 9.  New concepts of complement in allorecognition and graft rejection.

Authors:  Barbara A Wasowska; Chih-Yuan Lee; Marc K Halushka; William M Baldwin
Journal:  Cell Immunol       Date:  2007-10-24       Impact factor: 4.868

10.  Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

Authors:  Guillermina Girardi; Jessica Berman; Patricia Redecha; Lynn Spruce; Joshua M Thurman; Damian Kraus; Travis J Hollmann; Paolo Casali; Michael C Caroll; Rick A Wetsel; John D Lambris; V Michael Holers; Jane E Salmon
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.